Mixing Business And Philanthropy Yields Returns For Glaxo In Africa
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline is having success with its "hybrid" approach in Africa, combining no-nonsense business with the aim of improving access to medicines there – in part through deeply discounted prices, measuring managers’ sales performances by the amount of drugs sold, rather than profits, and reinvesting in health infrastructure.